Xiaoyu Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyu Wu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Genqing Zhou
Department of Cardiology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
3 shared publications - Zikan Zhong
Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Jiaqi Shen
Quyang Community Health Service Center of Hongkou District, Shanghai 200437, China
2 shared publications - Linqun Zheng
Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
2 shared publications - Mei Kang
Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
2 shared publications - Qitong Zhang
Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
2 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (11) , 606
Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Background: Menstrual changes during antithrombotic therapy for cardiovascular disease remain incompletely characterized. Methods: In a prospective observational cohort, we compared enrollment and follow-up menstrual assessments from 50 menstruating women treated for cardiovascular indications, including atrial fibrillation/flutter and coronary disease. We assessed within-person changes in menstrual-cycle classification and bleeding duration, together with bleeding-related documentation, healthcare visits, and absences. Results: The proportion with an abnormal cycle classification increased by 12.0 percentage points (95% CI, 2.0–22.6; 50 pairs), and the proportion reporting menses lasting at least 8 days increased by 12.5 percentage points (95% CI, 2.1–24.8; 48 pairs). For each outcome, six women newly met the definition and none ceased to meet it (exact McNemar p = 0.031). A documentation-based bleeding indicator was present in 17 of 46 evaluable women (37.0%). Menstrual-related healthcare visits and absences were reported by 13 and 6 women, respectively. Comparisons across treatment groups were exploratory because groups were small and differed by cardiovascular indication. Conclusions: Menstrual changes and related healthcare use and absences were observed during cardiovascular antithrombotic care. Routine assessment of menstrual symptoms may help identify women who need further evaluation and support.
- 17 November 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (11) , 606
Open AccessMenstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Background: Menstrual changes during antithrombotic therapy for cardiovascular disease remain incompletely characterized. Methods: In a prospective observational cohort, we compared enrollment and follow-up menstrual assessments from 50 menstruating women treated for cardiovascular indications, including atrial fibrillation/flutter and coronary disease. We assessed within-person changes in menstrual-cycle classification and bleeding duration, together with bleeding-related documentation, healthcare visits, and absences. Results: The proportion with an abnormal cycle classification increased by 12.0 percentage points (95% CI, 2.0–22.6; 50 pairs), and the proportion reporting menses lasting at least 8 days increased by 12.5 percentage points (95% CI, 2.1–24.8; 48 pairs). For each outcome, six women newly met the definition and none ceased to meet it (exact McNemar p = 0.031). A documentation-based bleeding indicator was present in 17 of 46 evaluable women (37.0%). Menstrual-related healthcare visits and absences were reported by 13 and 6 women, respectively. Comparisons across treatment groups were exploratory because groups were small and differed by cardiovascular indication. Conclusions: Menstrual changes and related healthcare use and absences were observed during cardiovascular antithrombotic care. Routine assessment of menstrual symptoms may help identify women who need further evaluation and support.
- Open Access
- 23 October 2026
- Published by MDPI AG in Preprints.org
Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Background: Abnormal uterine bleeding is a clinically important but often overlooked concern during antithrombotic therapy, particularly in cardiovascular care where anticoagulant and antiplatelet regimens are used. Objective: To describe paired menstrual changes during cardiovascular antithrombotic therapy and to explore documented increased or prolonged bleeding across treatment classes and observed regimens. Methods: This prospective observational paired clinical follow-up study included 50 menstruating women aged 18–55 years with regular menses who received antithrombotic therapy for cardiovascular conditions. Source records specified monthly follow-up and at least 3 months of anticipated treatment. Primary outcomes were paired changes in menstrual-cycle category and menstrual duration; documented increased or prolonged bleeding and variation across observed regimens were secondary exploratory outcomes. Results: Abnormal menstrual-cycle categories increased from 8/50 (16.0%) to 14/50 (28.0%), and prolonged menses increased from 2/49 (4.1%) to 8/49 (16.3%); both exact McNemar P=0.031. Documented increased or prolonged bleeding was recorded in 17/46 evaluable participants (37.0%). Menstrual-related healthcare use or absence was more frequent among those with documented bleeding than among those without it (9/17 vs 4/29; Fisher P = 0.007). The proportion with documented bleeding varied across seven observed regimens (P=0.006) and was highest among rivaroxaban recipients (13/19, 68.4%). Conclusions: Menstrual changes and bleeding-related clinical burden were observed during follow-up in women receiving antithrombotic therapy for cardiovascular conditions. The proportion with documented bleeding varied across observed regimens and was highest among rivaroxaban recipients. Larger prospective studies using standardized menstrual outcome measures are needed to evaluate between-regimen differences.
- 23 October 2026
- Published by MDPI AG in Preprints.org
Open AccessMenstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Background: Abnormal uterine bleeding is a clinically important but often overlooked concern during antithrombotic therapy, particularly in cardiovascular care where anticoagulant and antiplatelet regimens are used. Objective: To describe paired menstrual changes during cardiovascular antithrombotic therapy and to explore documented increased or prolonged bleeding across treatment classes and observed regimens. Methods: This prospective observational paired clinical follow-up study included 50 menstruating women aged 18–55 years with regular menses who received antithrombotic therapy for cardiovascular conditions. Source records specified monthly follow-up and at least 3 months of anticipated treatment. Primary outcomes were paired changes in menstrual-cycle category and menstrual duration; documented increased or prolonged bleeding and variation across observed regimens were secondary exploratory outcomes. Results: Abnormal menstrual-cycle categories increased from 8/50 (16.0%) to 14/50 (28.0%), and prolonged menses increased from 2/49 (4.1%) to 8/49 (16.3%); both exact McNemar P=0.031. Documented increased or prolonged bleeding was recorded in 17/46 evaluable participants (37.0%). Menstrual-related healthcare use or absence was more frequent among those with documented bleeding than among those without it (9/17 vs 4/29; Fisher P = 0.007). The proportion with documented bleeding varied across seven observed regimens (P=0.006) and was highest among rivaroxaban recipients (13/19, 68.4%). Conclusions: Menstrual changes and bleeding-related clinical burden were observed during follow-up in women receiving antithrombotic therapy for cardiovascular conditions. The proportion with documented bleeding varied across observed regimens and was highest among rivaroxaban recipients. Larger prospective studies using standardized menstrual outcome measures are needed to evaluate between-regimen differences.
- Open Access
- 13 September 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (2) , 435-458
Long Non-coding RNA Involved in the Pathophysiology of Atrial Fibrillation
Background: Atrial fibrillation (AF) is a prevalent and chronic cardiovascular disorder associated with various pathophysiological alterations, including atrial electrical and structural remodeling, disrupted calcium handling, autonomic nervous system dysfunction, aberrant energy metabolism, and immune dysregulation. Emerging evidence suggests that long non-coding RNAs (lncRNAs) play a significant role in the pathogenesis of AF. Objective: This discussion aims to elucidate the involvement of AF-related lncRNAs, with a specific focus on their role as miRNA sponges that modulate crucial signaling pathways, contributing to the progression of AF. We also address current limitations in AF-related lncRNA research and explore potential future directions in this field. Additionally, we summarize feasible strategies and promising delivery systems for targeting lncRNAs in AF therapy. Conclusion: In conclusion, targeting AF-related lncRNAs holds substantial promise for future investigations and represents a potential therapeutic avenue for managing AF.
- 13 September 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (2) , 435-458
Open AccessLong Non-coding RNA Involved in the Pathophysiology of Atrial Fibrillation
Background: Atrial fibrillation (AF) is a prevalent and chronic cardiovascular disorder associated with various pathophysiological alterations, including atrial electrical and structural remodeling, disrupted calcium handling, autonomic nervous system dysfunction, aberrant energy metabolism, and immune dysregulation. Emerging evidence suggests that long non-coding RNAs (lncRNAs) play a significant role in the pathogenesis of AF. Objective: This discussion aims to elucidate the involvement of AF-related lncRNAs, with a specific focus on their role as miRNA sponges that modulate crucial signaling pathways, contributing to the progression of AF. We also address current limitations in AF-related lncRNA research and explore potential future directions in this field. Additionally, we summarize feasible strategies and promising delivery systems for targeting lncRNAs in AF therapy. Conclusion: In conclusion, targeting AF-related lncRNAs holds substantial promise for future investigations and represents a potential therapeutic avenue for managing AF.